PRITHVIRAJ BOSE to Piperidines
This is a "connection" page, showing publications PRITHVIRAJ BOSE has written about Piperidines.
Connection Strength
0.684
-
Orphan drug designation for pracinostat, volasertib and alvocidib in AML. Leuk Res. 2014 Aug; 38(8):862-5.
Score: 0.319
-
Ibrutinib dose and clinical outcome in chronic lymphocytic leukemia - learning from the 'real world'. Leuk Lymphoma. 2019 07; 60(7):1603-1605.
Score: 0.110
-
Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies. Cancer Chemother Pharmacol. 2012 Jun; 69(6):1657-67.
Score: 0.068
-
Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol. 2021 Aug 01; 7(8):1213-1219.
Score: 0.033
-
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia. 2021 12; 35(12):3421-3429.
Score: 0.032
-
Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019 05 30; 380(22):2095-2103.
Score: 0.028
-
A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood. 2018 11 22; 132(21):2249-2259.
Score: 0.027
-
Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7?+?3) in newly diagnosed high-risk acute myeloid leukemia (AML). Leuk Res. 2018 09; 72:92-95.
Score: 0.027
-
Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. Haematologica. 2015 Sep; 100(9):1172-9.
Score: 0.021
-
Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clin Cancer Res. 2014 Nov 15; 20(22):5652-62.
Score: 0.020